Bayer

Page 3 of 6

Monsanto Charged $2 Billion In Damages For Weed Killer Roundup Cancer Lawsuit
International

Bayer reaches verbal deal to settle up to 85,000 Roundup cancer lawsuits

By Jef Feeley, Tim Loh and Bloomberg
May 25, 2020
Roundup weedkiller cancer claims soar as coronavirus outbreak complicates settlement talks
Finance

Roundup weedkiller cancer claims soar as coronavirus outbreak complicates settlement talks

By Tim Loh and Bloomberg
April 27, 2020
Paul Hudson, chief executive officer of Sanofi, gestures as he speaks during a panel session on the sidelines of the China International Import Expo (CIIE) in Shanghai, China, on Tuesday, Nov. 5, 2019. The CIIE -- now in its second year -- is designed to showcase the countrys desire to shift its economy toward consumption by buying more foreign goods. Photographer: Qilai Shen/Bloomberg via Getty Images
Newsletters

Big pharma’s big chance

By Katherine Dunn and Alan Murray
April 3, 2020
The CEO of German chemicals giant Bayer, Werner Baumann, speaks during the company's annual news conference in Leverkusen, western Germany, on February 27, 2020. - German chemical and pharmaceutical giant Bayer reported surging profits for 2019 after its buying US seeds and pesticides maker Monsanto, but remained entangled in a massive wave of lawsuits over a flagship weedkiller. (Photo by Ina FASSBENDER / AFP) (Photo by INA FASSBENDER/AFP via Getty Images)
International

Bayer says Roundup legal fiasco may force it to sell assets or borrow on bad terms

By Tim Loh and Bloomberg
February 27, 2020
A sign for Monsanto Co. Xtendimax herbicide, a dicamba product developed to combat "superweeds" resistant to RoundUp glyphosate herbicide, hangs in the Monsanto booth during the Farm Progress Show in Decatur, Illinois, U.S., on Tuesday, Aug. 29, 2017. The show, sponsored by Farm Progress Co. and owned by Penton Media, is billed as the largest outdoor farm show in the U.S. Photographer: Daniel Acker/Bloomberg via Getty Images
International

Bayer is facing a new wave of herbicide lawsuits—and this time it’s not over Monsanto’s Roundup

By Jef Feeley, Tim Bross and Bloomberg
February 17, 2020
Roundup weed killer is the subject of thousands of lawsuits in the U.S. It has been blamed for ailments including non-Hodgkin’s lymphoma, which can take years to diagnose.
Health

Bayer may pay $10 billion to settle Roundup cancer cases from its Monsanto deal

By Jef Feeley, Tim Loh and Bloomberg
January 24, 2020
Roundup weed killer that is the subject of thousands of lawsuits in the US, is pictured on sale in Los Angeles, California on September 1, 2019. (Photo by Mark RALSTON / AFP) (Photo credit should read MARK RALSTON/AFP/Getty Images)
Finance

As Roundup Lawsuits Pile Up by the Thousands, Bayer Remains Defiant

By
October 30, 2019
Roundup weed killer that is the subject of thousands of lawsuits in the US, is pictured on sale in Los Angeles, California on September 1, 2019. (Photo by Mark RALSTON / AFP) (Photo credit should read MARK RALSTON/AFP/Getty Images)
International

Bayer’s $30 Billion Roundup Crisis Heats Up as It Braces for a ‘Significant Surge’ of New Lawsuits

By Tim Loh and Bloomberg
October 16, 2019
Roundup weedkiller with rake
International

Bayer Wants to Settle All Roundup-Related Cancer Claims for $8 Billion

By Tim Loh, Joel Rosenblatt, Jef Feeley and Bloomberg
August 9, 2019
Roundup weed killer on store shelf
International

‘The Jump Is Worrying’: Bayer Reports Even More Roundup-Related Cancer Lawsuits

By Tim Loh and Bloomberg
July 30, 2019
Bayer AG Holds Annual Shareholders Meeting
International

Bayer Commits $5.6 Billion to Glyphosate Alternatives Amid 13,000 Lawsuits Over the Weedkiller

By Tim Loh, Naomi Kresge and Bloomberg
June 14, 2019
Bayer AG Holds Annual Shareholders Meeting
International

Bayer Has Now Lost Over 44% of Its Value Since Its Monsanto Merger

By
May 14, 2019
$80 Million Awarded To Man In Roundup Exposure Case
Health

The U.S. EPA Just Gave Bayer a Gift in Its Battle Against Weed Killer Cancer Claims

By
May 1, 2019
Bayer AG Holds Annual Shareholders Meeting
International

Bayer CEO Has 9 Months to Overcome Shareholders’ Extraordinary Rebuke of His Monsanto Deal

By
April 30, 2019
Bayer AG Holds Annual Shareholders Meeting
Health

Bayer’s Management Face A No-Confidence Vote Over Monsanto Deal. Here’s What You Need to Know.

By
April 26, 2019

Most Popular